NCT02155530

Brief Summary

This study is a prospective randomized trial to evaluate and compare the quantitative and qualitative characteristics of neointimal formation between high and low efficacy statin treatment after drug eluting stent (DES) implantation, in patients with homogeneous or heterogeneous neointimal pattern accessed by Optical Coherence Tomography (OCT). The investigators postulate that high efficacy statin could have superior effect on modification of neointimal pattern, compared with lower efficacy statin. Our main hypothesis is that Atorvastatin 40mg, high efficacy statin might have superior effect on modification of neointimal pattern evaluated by serially followed OCT, compared with pravastatin 20mg in patients with DES implantation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable coronary-artery-disease

Timeline
Completed

Started Jun 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2014

Completed
6 days until next milestone

Study Start

First participant enrolled

June 1, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 4, 2014

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

July 27, 2016

Status Verified

July 1, 2016

Enrollment Period

1.9 years

First QC Date

May 26, 2014

Last Update Submit

July 26, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of neointimal patterns assessed by 1-year followed OCT

    Qualitative neointimal pattern measured by OCT such as restenotic tissue structure

    at 1 year

Secondary Outcomes (2)

  • stent coverage and neointimal thickness

    at 1 year

  • Major adverse cardiac events

    at 1 year

Study Arms (2)

High efficacy statin group (homogeneous)

EXPERIMENTAL

homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group

Drug: Atorvastatin 40mg

Low efficacy statin group (homogeneous)

ACTIVE COMPARATOR

homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group

Drug: pravastatin 20 mg

Interventions

homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group

Also known as: Atorvastatin 40 mg (Homogeneous)
High efficacy statin group (homogeneous)

Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group

Also known as: Pravastatin 20 mg (Homogeneous)
Low efficacy statin group (homogeneous)

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient is ≥ 20 years old
  • Patients who received OCT related to clinical needs or the end point of other study
  • Patients who received DES within 1 year before OCT evaluation
  • Patients with homogenous or hetero neointimal pattern by OCT
  • Non-statin user and moderate or low efficacy statin user

You may not qualify if:

  • Refuse to participate
  • Contraindication to statin treatment
  • Women with current or potential childbearing
  • Life expectancy \<1 year
  • High efficacy statin user (Atorvastatin 80mg or Rosuvastatin 20mg)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, 120-752, South Korea

Location

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

AtorvastatinPravastatin

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

PyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeptanoic AcidsFatty AcidsLipidsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2014

First Posted

June 4, 2014

Study Start

June 1, 2014

Primary Completion

May 1, 2016

Study Completion

June 1, 2016

Last Updated

July 27, 2016

Record last verified: 2016-07

Locations